Sanjay Gupta from Imbed Biosciences Inc. Featured in The Wall Street Journal as a Distinguished Leader in Healthcare Supply Chain
MIDDLETON, Wis., May 30, 2025 /PRNewswire/ — Imbed Biosciences Inc., a leader in advanced wound care technology, is proud to announce that Sanjay Gupta, Vice President of Integrated Supply Chain, has been featured in The Wall Street Journal as one of the 2025 “Who’s Who of Distinguished Leaders” by Marquis Who’s Who®. This national recognition honors his outstanding leadership, industry contributions, and transformative impact on the global healthcare supply chain.
With over two decades of experience spanning the medical device and logistics industries, Gupta has been a driving force behind Imbed’s operational growth and innovation in the development of synthetic antimicrobial matrix technology for use in advanced wound care management. His leadership has been pivotal in scaling manufacturing operations, launching next-generation products, and expanding international market presence.
“Sanjay embodies what it means to be a strategic and compassionate leader,” said Terry Bromley, CEO of Imbed Biosciences. “His ability to align operational excellence with patient-centric outcomes has not only advanced our mission but positioned us for significant future growth.”
Under Gupta’s leadership, Imbed Biosciences scaled high-volume manufacturing and is spearheading the launch of new FDA-cleared products like Surgaflex™ SAM™ PainGuard™ with Lidocaine. Gupta drove international growth with the introduction of the Microlyte® SAM™ line in Latin America, and expanded distribution across Colombia, the UAE, and other markets. His efforts helped commercial growth of the company while ensuring quality, compliance, and rapid market readiness.
Out of more than 1.6 million professionals listed in the Marquis registry, only a small percentage are selected as Distinguished Leaders. The honor underscores Gupta’s commitment to operational innovation, global access, and the delivery of life-saving medical technologies.
About Imbed Biosciences Inc.
Imbed Biosciences is a privately held medical device company and innovator of SAM™ Antimicrobial Technology, with both commercially available and emerging, pipeline solutions for the treatment of acute, burn, chronic, and surgical wounds. Imbed’s revolutionary platform technology enhances skin regeneration by integrating multiple agents into an ultra-thin, biocompatible matrix to facilitate wound healing, redefining wound care globally.
Media Contact:
Hillary Rush
VP of Marketing
Imbed Biosciences Inc.
Email: media@imbedbio.com
Website: www.imbedbio.com
SOURCE Imbed Biosciences
After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…
Clemson University and Nordic Wellness have launched a pioneering partnership tackling the student mental health…
Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as…